- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Patent
High court rules against Indiana farmer in patent case
May 13, 2013
Associated PressThe Supreme Court has sustained Monsanto Co.'s claim that an Indiana farmer violated the company's patents on soybean
seeds that are resistant to its weed-killer.
MoreLilly suing J&J for patent rights in Alzheimer's drug race
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
MoreCourt may decide if drugmakers can pay to delay generics
March 25, 2013
Associated PressFederal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors
to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for
years, steep price declines.
MoreHigh court seems to favor Monsanto in patent case
February 19, 2013
Associated PressThe U.S. Supreme Court appeared likely Tuesday to side with Monsanto Co. in its claim that an Indiana farmer violated the
company's patents on soybean seeds that are resistant to its weed-killer.
MoreHigh-stakes fight over soybeans at high court
February 18, 2013
Associated PressThe court case poses the question of an Indiana farmer's actions violated the patent rights held by Monsanto, which developed
seeds that survive when farmers spray their fields with Roundup weed-killer. The seeds dominate agriculture, including in
Indiana, where more than 90 percent of soybeans are Roundup Ready.
MoreHoosier colleges discover patents aren't just for faculty anymore
November 10, 2012
Chris O'MalleyUniversities that once focused on faculty inventions now are encouraging students to pursue patents. Last year, 355 Purdue
University students filed a patent, a 62-percent jump from 218 student-filed patents the previous year.
MoreDow Agro awarded $5.3M in patent-infringement case
October 2, 2012
The unsuccessful lawsuit filed by a subsidiary of Belgium-based Bayer Bioscience claimed that insect-resistant corn products
from affiliates of Dow AgroSciences violated two of its patents.
MoreDow AgroSciences prevails in patent-infringement case
September 28, 2012
The lawsuit, filed in December 2010 by Bayer CropScience SA, charged that Indianapolis-based Dow AgroSciences' herbicide-tolerance
technology infringed one of its patents.
MoreLilly challenging Biogen patent in London lawsuit
January 5, 2012
Bloomberg NewsEli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system
diseases.
MorePatent expirations up pressure on Lilly
December 24, 2011
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into
the long-awaited zone of uncertainty that it calls “Years YZ.”
MoreJONES: Patent reform is mixed bag for life sciences companies
November 26, 2011
Kristin Jones / Special to IBJFor Indiana's life sciences sector, the change both raises hopes and creates challenges for continued growth.
MoreLilly files suit over flea medication sales from Australia
November 11, 2011
Scott OlsonThe Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's
trademark by reselling it to U.S. consumers online.
MoreBorgWarner sues Cummins over patents on turbochargers
October 27, 2011
Bloomberg NewsBorgWarner Inc., the world’s biggest maker of automatic-transmission parts for vehicles, filed a lawsuit accusing Cummins
Inc. of infringing on three patents for a titanium wheel used in engine turbochargers.
MoreZyprexa era comes to an end for Lilly
October 27, 2011
IBJ StaffOn Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller,
ending 15 years of highly lucrative sales.
MoreLilly: Vendors key after Zyprexa patent loss
October 24, 2011
J.K. WallLilly's patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more
on its 1,300 Indiana vendors.
MoreSenate passes overhaul of patent system
September 10, 2011
Bloomberg NewsThe legislation would fundamentally alter the way patents are reviewed and mark the biggest change to U.S. patent law since
at least 1952.
MoreDespite sales spike, Effient has middling prospects
July 25, 2011
J.K. WallRemember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow
launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
MoreLilly CEO: Immigration, tax laws slow innovation
June 23, 2011
Bloomberg NewsThe U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly
& Co. CEO John Lechleiter plans to tell a technology conference Thursday.
MoreGrowth in drug spending to slow as generics rise
May 18, 2011
Bloomberg NewsThe annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic
medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical
firms like Eli Lilly and Co. are facing.
MoreZimmer, peer sued over arthritic-knee treatments
April 26, 2011
Bloomberg NewsGenzyme Corp., the drugmaker bought by Sanofi-Aventis SA this month, sued Zimmer Holdings Inc. and Anika Therapeutics Inc.
alleging the companies’ treatments for arthritic knee pain infringe a patent.
MoreFirm joins race with IU autism drug
April 9, 2011
J.K. WallThe Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed
the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
MoreLechleiter: After the deluge, we'll be fine
March 16, 2011
J.K. WallEli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver
his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly
will be just fine after it has sustained the damage of the next three years.
MoreDow Chemical moves toward engineered corn patent
March 1, 2011
Associated PressDow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for
its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
MoreCongress takes up major change in patent law
February 28, 2011
Associated PressCongress has been trying for well over a decade to rewrite patent law, only to be thwarted by the many interested parties.
MoreIntellectual property theft rising quickly
February 26, 2011
Bob Kronemyer / Special to IBJFilching ranges from crude to highly sophisticated, experts say.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.